P404 Normal CRP remission as an outcome parameter in pediatric Crohn's disease: Evaluation of the Porto IBD Group “Growth Relapse and Outcomes With Therapy” (GROWTH CD) cohort study
M. Sładek(Jagiellonian University), A. Levine(Tel Aviv University), Ron Shaoul(Rambam Health Care Campus), Anders Pærregaard(Amager Hospital), J.C. Escher, Sibylle Koletzko(LMU Klinikum), Amanda E. Staiano(Pennington Biomedical Research Center), G. Veereman Wauters(Vrije Universiteit Brussel), G. Veres, Orit Shevah(Tel Aviv University), Tamar Pfeffer Gik(Tel Aviv University), Javier Martín de Carpi(Hospital Sant Joan de Déu Barcelona), K.-L. Kolho(Helsinki University Hospital), Dan Turner(Shaare Zedek Medical Center), L. Finnby(Lovisenberg Diakonale Sykehus), Jorge Amil Dias(Hospital de São João)
Cited by 0
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
ESPGHAN Revised Porto Criteria for the Diagnosis of Inflammatory Bowel Disease in Children and Adolescents
|Journal of Pediatric Gastroenterology and Nutrition|2013|1.4k
Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference
|Gastroenterology|2018|1.1k
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease
|Journal of Crohn s and Colitis|2014|1.1k
Screening of Probiotic Activities of Forty-Seven Strains of <i>Lactobacillus</i> spp. by In Vitro Techniques and Evaluation of the Colonization Ability of Five Selected Strains in Humans
|Applied and Environmental Microbiology|1999|868